Shares of TransUnion TRU have gained 35.5% over the past year, outperforming the 24.2% surge of the industry it belongs to.Image Source: Zacks Investment ResearchLet’s delve into factors that have contributed to the company’s outperformance.Consecutive Earnings & Revenue BeatTransUnion reported better-than-expected earnings and revenue performance in the last four quarters. While operating efficiency has been aiding the company’s bottom line, strength across segments benefit the top line.Upbeat 2021 GuidanceTransUnion has raised its guidance for 2021. Revenues are now expected to be between $2.949 billion and $2.992 billion compared with the prior guidance of $2.817-$2.877 billion. The Zacks Consensus Estimate of $2.98 billion lies within the updated guidance.Adjusted earnings are now expected between $3.45 and $3.58 per share compared with the prior guidance of $3.16-$3.31. The Zacks Consensus Estimate of $3.58 is on par with the upper limit of the updated guidance.Adjusted EBITDA is now anticipated to be between $1.157 billion and $1.189 billion compared with the prior guidance of $1.083-$1.121 billion.Dividend HikeOn May 12, 2021, TransUnion announced that its board of directors has declared a dividend hike of approximately 27% to 9.5 cents per share. The dividend was paid out to shareholders on Jun 10, as of record date May 26.During 2020, 2019 and 2018, TransUnion paid out dividends totaling $57.6 million, $56.8 million and $41.6 million, respectively. Such moves indicate the company’s commitment to create value for shareholders and also underline its confidence in its business. These shareholder-friendly initiatives not only instill investors’ confidence, but also positively impact earnings per share.Zacks Rank and Stocks to ConsiderTransUnion currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Some better-ranked stocks in the broader Zacks Business Servicessector include Paychex PAYX, Omnicom OMC and Interpublic IPG, each carrying a Zacks Rank #2 (Buy).Long-term (three to five years) expected earnings per share growth rate for Paychex, Omnicom and Interpublic is projected at 8%, 9.9% and 10.2%, respectively. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Paychex, Inc. (PAYX): Free Stock Analysis Report Omnicom Group Inc. (OMC): Free Stock Analysis Report Interpublic Group of Companies, Inc. The (IPG): Free Stock Analysis Report TransUnion (TRU): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research